Frontiers in Cellular Neuroscience (Dec 2022)
Telomere length analysis in amyotrophic lateral sclerosis using large-scale whole genome sequence data
- Ahmad Al Khleifat,
- Alfredo Iacoangeli,
- Alfredo Iacoangeli,
- Ashley R. Jones,
- Joke J. F. A. van Vugt,
- Matthieu Moisse,
- Matthieu Moisse,
- Aleksey Shatunov,
- Aleksey Shatunov,
- Ramona A. J. Zwamborn,
- Rick A. A. van der Spek,
- Johnathan Cooper-Knock,
- Simon Topp,
- Wouter van Rheenen,
- Brendan Kenna,
- Kristel R. Van Eijk,
- Kevin Kenna,
- Ross Byrne,
- Victoria López,
- Sarah Opie-Martin,
- Atay Vural,
- Yolanda Campos,
- Markus Weber,
- Markus Weber,
- Bradley Smith,
- Isabella Fogh,
- Vincenzo Silani,
- Vincenzo Silani,
- Karen E. Morrison,
- Richard Dobson,
- Richard Dobson,
- Michael A. van Es,
- Russell L. McLaughlin,
- Patrick Vourc’h,
- Adriano Chio,
- Adriano Chio,
- Philippe Corcia,
- Philippe Corcia,
- Mamede de Carvalho,
- Marc Gotkine,
- Monica Povedano Panades,
- Jesus S. Mora,
- Pamela J. Shaw,
- John E. Landers,
- Jonathan D. Glass,
- Christopher E. Shaw,
- Christopher E. Shaw,
- Nazli Basak,
- Orla Hardiman,
- Orla Hardiman,
- Wim Robberecht,
- Wim Robberecht,
- Philip Van Damme,
- Philip Van Damme,
- Leonard H. van den Berg,
- Jan H. Veldink,
- Ammar Al-Chalabi,
- Ammar Al-Chalabi
Affiliations
- Ahmad Al Khleifat
- Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King’s College London, London, United Kingdom
- Alfredo Iacoangeli
- Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King’s College London, London, United Kingdom
- Alfredo Iacoangeli
- Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom
- Ashley R. Jones
- Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King’s College London, London, United Kingdom
- Joke J. F. A. van Vugt
- Department of Neurology, University Medical Center (UMC) Utrecht Brain Center, Utrecht University, Utrecht, Netherlands
- Matthieu Moisse
- Department of Neurosciences, Experimental Neurology, KU Leuven—University of Leuven, Leuven, Belgium
- Matthieu Moisse
- VIB Center for Brain & Disease Research, Laboratory of Neurobiology, Leuven, Belgium
- Aleksey Shatunov
- Institute of Medicine, North-Eastern Federal University, Yakutsk, Russia
- Aleksey Shatunov
- Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom
- Ramona A. J. Zwamborn
- Department of Neurology, University Medical Center (UMC) Utrecht Brain Center, Utrecht University, Utrecht, Netherlands
- Rick A. A. van der Spek
- Department of Neurology, University Medical Center (UMC) Utrecht Brain Center, Utrecht University, Utrecht, Netherlands
- Johnathan Cooper-Knock
- Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, United Kingdom
- Simon Topp
- Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King’s College London, London, United Kingdom
- Wouter van Rheenen
- Department of Neurology, University Medical Center (UMC) Utrecht Brain Center, Utrecht University, Utrecht, Netherlands
- Brendan Kenna
- Department of Neurology, University Medical Center (UMC) Utrecht Brain Center, Utrecht University, Utrecht, Netherlands
- Kristel R. Van Eijk
- Department of Neurology, University Medical Center (UMC) Utrecht Brain Center, Utrecht University, Utrecht, Netherlands
- Kevin Kenna
- Department of Neurology, University Medical Center (UMC) Utrecht Brain Center, Utrecht University, Utrecht, Netherlands
- Ross Byrne
- Complex Trait Genomics Laboratory, Smurfit Institute of Genetics, Trinity College Dublin, Dublin, Ireland
- Victoria López
- 0Computational Biology Unit, Instituto de Salud Carlos III, Madrid, Spain
- Sarah Opie-Martin
- Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King’s College London, London, United Kingdom
- Atay Vural
- 1School of Medicine, Translational Medicine Research Center-NDAL, Koc University, Istanbul, Turkey
- Yolanda Campos
- 0Computational Biology Unit, Instituto de Salud Carlos III, Madrid, Spain
- Markus Weber
- 1School of Medicine, Translational Medicine Research Center-NDAL, Koc University, Istanbul, Turkey
- Markus Weber
- 2Neuromuscular Diseases Unit/ALS Clinic, Kantonsspital St. Gallen, St. Gallen, Switzerland
- Bradley Smith
- Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King’s College London, London, United Kingdom
- Isabella Fogh
- Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King’s College London, London, United Kingdom
- Vincenzo Silani
- 3Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy
- Vincenzo Silani
- 4Department of Pathophysiology and Transplantation, “Dino Ferrari” Center, Università degli Studi di Milano, Milan, Italy
- Karen E. Morrison
- 5Faculty of Medicine, Health and Life Sciences, Queen’s University Belfast, Belfast, United Kingdom
- Richard Dobson
- Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom
- Richard Dobson
- 6Institute of Health Informatics, University College London, London, United Kingdom
- Michael A. van Es
- Department of Neurology, University Medical Center (UMC) Utrecht Brain Center, Utrecht University, Utrecht, Netherlands
- Russell L. McLaughlin
- Complex Trait Genomics Laboratory, Smurfit Institute of Genetics, Trinity College Dublin, Dublin, Ireland
- Patrick Vourc’h
- 7Centre SLA, CHRU de Tours, Tours, France
- Adriano Chio
- 8Department of Neuroscience, ALS Centre, University of Torino, Turin, Italy
- Adriano Chio
- 9Azienda Ospedaliera Citta della Salute e della Scienza, Turin, Italy
- Philippe Corcia
- 7Centre SLA, CHRU de Tours, Tours, France
- Philippe Corcia
- 0Federation des Centres SLA Tours and Limoges, LITORALS, Tours, France
- Mamede de Carvalho
- 1Physiology Institute, Faculty of Medicine, Instituto de Medicina Molecular, University of Lisbon, Lisbon, Portugal
- Marc Gotkine
- 2Department of Neurology, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
- Monica Povedano Panades
- 3Department of Neurology, Hospital Universitari de Bellvitge, Barcelona, Spain
- Jesus S. Mora
- 4Hospital San Rafael, Madrid, Spain
- Pamela J. Shaw
- Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, United Kingdom
- John E. Landers
- 5Department of Neurology, University of Massachusetts Medical School, Worcester, MA, United States
- Jonathan D. Glass
- 6Department of Neurology, Center for Neurodegenerative Diseases, Emory University, Atlanta, GA, United States
- Christopher E. Shaw
- Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King’s College London, London, United Kingdom
- Christopher E. Shaw
- 7King’s College Hospital, London, United Kingdom
- Nazli Basak
- 1School of Medicine, Translational Medicine Research Center-NDAL, Koc University, Istanbul, Turkey
- Orla Hardiman
- 8Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland
- Orla Hardiman
- 9Department of Neurology, Beaumont Hospital, Dublin, Ireland
- Wim Robberecht
- Department of Neurosciences, Experimental Neurology, KU Leuven—University of Leuven, Leuven, Belgium
- Wim Robberecht
- 0Department of Neurology, University Hospitals Leuven, Leuven, Belgium
- Philip Van Damme
- Department of Neurosciences, Experimental Neurology, KU Leuven—University of Leuven, Leuven, Belgium
- Philip Van Damme
- 0Department of Neurology, University Hospitals Leuven, Leuven, Belgium
- Leonard H. van den Berg
- Department of Neurology, University Medical Center (UMC) Utrecht Brain Center, Utrecht University, Utrecht, Netherlands
- Jan H. Veldink
- Department of Neurology, University Medical Center (UMC) Utrecht Brain Center, Utrecht University, Utrecht, Netherlands
- Ammar Al-Chalabi
- Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King’s College London, London, United Kingdom
- Ammar Al-Chalabi
- 7King’s College Hospital, London, United Kingdom
- DOI
- https://doi.org/10.3389/fncel.2022.1050596
- Journal volume & issue
-
Vol. 16
Abstract
BackgroundAmyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the loss of upper and lower motor neurons, leading to progressive weakness of voluntary muscles, with death following from neuromuscular respiratory failure, typically within 3 to 5 years. There is a strong genetic contribution to ALS risk. In 10% or more, a family history of ALS or frontotemporal dementia is obtained, and the Mendelian genes responsible for ALS in such families have now been identified in about 50% of cases. Only about 14% of apparently sporadic ALS is explained by known genetic variation, suggesting that other forms of genetic variation are important. Telomeres maintain DNA integrity during cellular replication, differ between sexes, and shorten naturally with age. Sex and age are risk factors for ALS and we therefore investigated telomere length in ALS.MethodsSamples were from Project MinE, an international ALS whole genome sequencing consortium that includes phenotype data. For validation we used donated brain samples from motor cortex from people with ALS and controls. Ancestry and relatedness were evaluated by principal components analysis and relationship matrices of DNA microarray data. Whole genome sequence data were from Illumina HiSeq platforms and aligned using the Isaac pipeline. TelSeq was used to quantify telomere length using whole genome sequence data. We tested the association of telomere length with ALS and ALS survival using Cox regression.ResultsThere were 6,580 whole genome sequences, reducing to 6,195 samples (4,315 from people with ALS and 1,880 controls) after quality control, and 159 brain samples (106 ALS, 53 controls). Accounting for age and sex, there was a 20% (95% CI 14%, 25%) increase of telomere length in people with ALS compared to controls (p = 1.1 × 10−12), validated in the brain samples (p = 0.03). Those with shorter telomeres had a 10% increase in median survival (p = 5.0×10−7). Although there was no difference in telomere length between sporadic ALS and familial ALS (p=0.64), telomere length in 334 people with ALS due to expanded C9orf72 repeats was shorter than in those without expanded C9orf72 repeats (p = 5.0×10−4).DiscussionAlthough telomeres shorten with age, longer telomeres are a risk factor for ALS and worsen prognosis. Longer telomeres are associated with ALS.
Keywords
- amyotrophic lateral sclerosis (ALS)
- telomere–genetics
- whole genome sequence (WGS)
- genomics
- bigdata
- MND–motor neuron disorders